AzurRx BioPharma, Inc.
AZRX · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $6 | $9 | $5 |
| G&A Expenses | $15 | $7 | $6 | $8 |
| SG&A Expenses | $15 | $7 | $6 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $21 | $0 | $0 |
| Operating Expenses | $16 | $26 | $15 | $13 |
| Operating Income | -$16 | -$26 | -$15 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$6 | -$0 | -$0 |
| Pre-Tax Income | -$18 | -$33 | -$15 | -$14 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$18 | -$33 | -$15 | -$14 |
| % Margin | – | – | – | – |
| EPS | -5.33 | -5.903 | -6.77 | -8.77 |
| % Growth | 9.7% | 12.8% | 22.8% | – |
| EPS Diluted | -5.33 | -5.903 | -6.77 | -8.77 |
| Weighted Avg Shares Out | 3 | 6 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 6 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $6 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$16 | -$27 | -$14 | -$13 |
| % Margin | – | – | – | – |